Pfizer’s shares sank significantly on Tuesday as global markets rose steadily. Analysts downgraded the firm over weak drug prospects. Some investors worry the pipeline lacks depth and leadership stays uncertain.
But Pfizer won a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. Still, the stock losses eclipsed the good news. Offices in Midtown Manhattan were evacuated after beams gave way, sparking collapse concerns.